Related Experiment Video

Updated: Jan 2, 2026

Author Spotlight: Insights into Cardiometabolic Diseases with Subcutaneous Adipose Tissue Microvasculature Studies
06:35

Author Spotlight: Insights into Cardiometabolic Diseases with Subcutaneous Adipose Tissue Microvasculature Studies

Published on: April 5, 2024

1.5K

Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration

Lee-Shing Chang1, Muthiah Vaduganathan2, Jorge Plutzky2

  • 1Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, 221 Longwood Avenue, RFB-2, Boston, MA, 02115, USA. lchang12@bwh.harvard.edu.

Current Diabetes Reports
|December 6, 2019
PubMed
Abstract

Insights

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1 RA) reduce cardiovascular risk in type 2 diabetes (T2D). Collaborative care models improve management for patients with T2D and cardiovascular disease (CVD).

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Cardiovascular disease (CVD) is a primary cause of death in type 2 diabetes (T2D).
  • Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1 RA) offer significant cardiovascular benefits beyond glucose control in T2D patients.

Purpose of the Study:

  • To review current models of cardiometabolic care for patients with diabetes and CVD.
  • To discuss collaborative strategies between diabetes and cardiovascular specialists for improved patient outcomes.

Main Methods:

  • Review of recent cardiovascular outcome trials (CVOTs) for SGLT2i and GLP1 RA.
  • Analysis of proposed and existing models of cardiometabolic care.

Main Results:

  • SGLT2i and GLP1 RA significantly reduce major adverse cardiovascular events in T2D patients.
  • Various care models, including multidisciplinary clinics and remote management, enhance care for complex patients.
  • Collaboration between specialists optimizes diabetes and cardiovascular care.

Conclusions:

  • Innovative cardiometabolic care models can enhance the quality of care for individuals with T2D and CVD.
  • Co-management by diabetes specialists, cardiovascular specialists, and primary care providers is crucial for optimizing patient management.
Keywords:
CardiometabolicCardiovascular outcome trialsGLP1 receptor agonistsSGLT2 inhibitorsType 2 diabetes

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.1K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
282
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
196
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
809
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
203
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
268